Madrigal Pharmaceuticals Appoints New CMO, Elects Directors
Ticker: MDGL · Form: 8-K · Filed: Jun 27, 2024 · CIK: 1157601
Sentiment: neutral
Topics: executive-appointment, board-election, leadership-change
Related Tickers: MDGL
TL;DR
Madrigal Pharma gets a new CMO and two board members. Leadership shakeup!
AI Summary
Madrigal Pharmaceuticals, Inc. announced on June 25, 2024, the appointment of Dr. Elias J. Growe as Chief Medical Officer, effective immediately. Dr. Growe previously served as Senior Vice President, Clinical Development at the company. The company also announced the election of two new directors, Dr. Steven M. Ferguson and Ms. Sarah E. Kelly, to its Board of Directors.
Why It Matters
These executive and board changes could signal strategic shifts in leadership and governance for Madrigal Pharmaceuticals, potentially impacting its future drug development and business strategy.
Risk Assessment
Risk Level: low — The filing primarily concerns routine executive and board appointments, with no immediate financial distress or significant operational changes indicated.
Key Players & Entities
- Madrigal Pharmaceuticals, Inc. (company) — Registrant
- Dr. Elias J. Growe (person) — Appointed Chief Medical Officer
- Dr. Steven M. Ferguson (person) — Elected to Board of Directors
- Ms. Sarah E. Kelly (person) — Elected to Board of Directors
- June 25, 2024 (date) — Effective date of appointments
FAQ
Who has been appointed as the new Chief Medical Officer of Madrigal Pharmaceuticals?
Dr. Elias J. Growe has been appointed as the new Chief Medical Officer, effective immediately.
When was Dr. Elias J. Growe appointed as Chief Medical Officer?
Dr. Elias J. Growe was appointed Chief Medical Officer effective June 25, 2024.
Who are the newly elected directors to Madrigal Pharmaceuticals' Board?
Dr. Steven M. Ferguson and Ms. Sarah E. Kelly have been elected as new directors.
What was Dr. Elias J. Growe's previous role at Madrigal Pharmaceuticals?
Dr. Growe previously served as Senior Vice President, Clinical Development at Madrigal Pharmaceuticals.
What is the effective date of the reported changes in directors and officers?
The earliest event reported is dated June 25, 2024.
Filing Stats: 1,024 words · 4 min read · ~3 pages · Grade level 11.1 · Accepted 2024-06-27 16:28:01
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MDGL The NASDAQ
Filing Documents
- d839852d8k.htm (8-K) — 41KB
- d839852dex101.htm (EX-10.1) — 104KB
- g839852g0626231722996.jpg (GRAPHIC) — 4KB
- 0001193125-24-170634.txt ( ) — 305KB
- mdgl-20240625.xsd (EX-101.SCH) — 3KB
- mdgl-20240625_lab.xml (EX-101.LAB) — 18KB
- mdgl-20240625_pre.xml (EX-101.PRE) — 11KB
- d839852d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MADRIGAL PHARMACEUTICALS, INC. Date: June 27, 2024 By: /s/ Mardi C. Dier Mardi C. Dier Senior Vice President and Chief Financial Officer